[Update in hereditary angioedema due to C1 inhibitor deficiency].
Sección de Alergología, Servicio de Medicina Interna, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. mguilart@Vhebron.Net
Mar
M
Guilarte
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001920:Bradykinin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D018450:Disease Progression; D056829:Hereditary Angioedema Types I and II / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D010455:Peptides / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D010455:Peptides; D011994:Recombinant Proteins; C469952:SERPING1 protein, human; C511194:ecallantide; C571093:conestat alfa; C065679:icatibant; D001920:Bradykinin